deltatrials
Completed PHASE2 NCT00005865

Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

A Research Study Evaluating Oral and Intravenous NAVELBINE as a Single Agent for the Treatment of Chemotherapy-Naive Subjects With Inoperable Stage IIIb or Stage IV Non-Small Cell Lung Cancer

Sponsor: GlaxoSmithKline

Conditions Lung Cancer
Interventions vinorelbine tartrate
Updated 6 times since 2017 Last updated: Jan 3, 2014 Started: Apr 30, 2000 Completion: Jun 30, 2007

This PHASE2 trial investigates Lung Cancer and is currently completed. GlaxoSmithKline leads this study, which shows 6 recorded versions since 2000 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Apr 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States, Baton Rouge, United States, Boca Raton, United States, Buffalo, United States, Burlington, United States, Chicago, United States, Cleveland, United States, Columbus, United States, Dallas, United States, Detroit, United States and 34 more location s